Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Myopia Control With the Multi-segment Lens

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02206217
Recruitment Status : Completed
First Posted : August 1, 2014
Results First Posted : July 31, 2019
Last Update Posted : July 31, 2019
Sponsor:
Collaborator:
HOYA Corporation (Tokyo, Japan)
Information provided by (Responsible Party):
Carly Lam, The Hong Kong Polytechnic University

Brief Summary:

The purpose of this study is to determine if the Multiple-Segment (MS) spectacle lens can slow myopia progression in Hong Kong schoolchildren.

MS lens is also called Defocus Incorporated Multiple Segments (DIMS) spectacle lens


Condition or disease Intervention/treatment Phase
Myopia Device: Multiple-Segment spectacle lens Not Applicable

Detailed Description:
MS lens is a novel lens designed in attempt to slow myopia progression. It is a multifocal spectacle lens which corrects distance refractive error and at the same time produces myopic defocus images on the retina for all distances. The myopic defocus aims at slowing down myopia progression. The purpose of this study is to investigate if the MS lens can slow myopia progression in Hong Kong Chinese schoolchildren. The subjects will be randomly assigned to either treatment group (wear MS lenses) or control group (wear ordinary single vision lenses). Their cycloplegic refraction and axial length will be monitored every six months over 2 years. The changes in refractive errors and axial length in two groups will be compared.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 183 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Clinical Trial of Myopia Control in Schoolchildren Using the Multi-segment (MS) Lens
Actual Study Start Date : August 2014
Actual Primary Completion Date : July 2017
Actual Study Completion Date : July 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eye Wear

Arm Intervention/treatment
No Intervention: Single vision spectacle lens
Single vision lens with power for correcting distance refraction.
Experimental: Multiple-Segment spectacle lens
A multifocal spectacle lens that corrects distance refraction and provides myopic defocus at the same time.
Device: Multiple-Segment spectacle lens
A multifocal spectacle lens that corrects distance refraction and provides myopic defocus images simultaneously. The myopic defocus aims at slowing down myopia progression.
Other Name: MS lens




Primary Outcome Measures :
  1. Cycloplegic Refraction Change in SER [ Time Frame: Baseline and 2 years ]
    Change in cycloplegic SER (in diopter) that was measured using Shin-Nippon NVision-K 5001 autorefractor.


Secondary Outcome Measures :
  1. Axial Length [ Time Frame: Baseline and 2 years ]
    Axial length (mm) was measured after cycloplegia using IOL Master



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   8 Years to 13 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age at enrolment: 8-13 year
  • Spherical equivalent refractions (SER): -1.00 to -5.00 Dioptres (D)
  • Astigmatism and anisometropia of 1.50 D or less
  • Spectacle corrected monocular logMAR visual acuity: 0 or better
  • Parents' understanding and acceptance of random allocation of grouping

Exclusion Criteria:

  • any ocular and systemic abnormalities might affect visual functions or refractive development
  • prior treatment of myopic control, e.g. drugs, orthokeratology, progressive addition lenses, bifocal lenses, drugs (e.g. atropine), etc.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02206217


Locations
Layout table for location information
China
Centre for Myopia Research, The Hong Kong Polytechnic University
Hong Kong, China
Hong Kong
Centre for Myopia Research, The Hong Kong Polytechnic University
Hong Kong, Hong Kong
Sponsors and Collaborators
The Hong Kong Polytechnic University
HOYA Corporation (Tokyo, Japan)
Investigators
Layout table for investigator information
Principal Investigator: Carly SY Lam, PhD The Hong Kong Polytechnic University
Principal Investigator: Chi ho To, PhD The Hong Kong Polytechnic University
  Study Documents (Full-Text)

Documents provided by Carly Lam, The Hong Kong Polytechnic University:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Carly Lam, Professor, The Hong Kong Polytechnic University
ClinicalTrials.gov Identifier: NCT02206217     History of Changes
Other Study ID Numbers: H-ZG3B
First Posted: August 1, 2014    Key Record Dates
Results First Posted: July 31, 2019
Last Update Posted: July 31, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Myopia
Refractive Errors
Eye Diseases